RD140 injection for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental injection called RD140 for people with multiple myeloma or plasma cell leukemia that has come back or not responded to previous treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have multiple myeloma or primary plasma cell leukemia.
- You have tried at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
- Your disease has progressed despite treatment or within 12 months after your last treatment.
- You have measurable signs of the disease, such as a certain level of M protein in blood or urine, or a high percentage of plasma cells in your bone marrow.
- You are generally in good health (ECOG score 0 or 1) and your organs are functioning well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.